# Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

> **NCT01660763** · PHASE3 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 419 (actual)

## Conditions studied

- Post Operative Pain

## Interventions

- **DRUG:** Sufentanil NanoTab PCA System/15 mcg
- **DRUG:** Placebo Sufentanil NanoTab PCA System

## Key facts

- **NCT ID:** NCT01660763
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-04
- **Final completion:** 2013-05
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660763, "Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01660763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*